|
Patent landscape, scope, and claims: |
United States Drug Patent 8,293,756: Scope, Claims, and Landscape Analysis
Patent 8,293,756, titled "Antisense Oligonucleotides," was granted to Ionis Pharmaceuticals, Inc. on October 23, 2012. The patent covers a method of treating dyslipidemias, specifically hypercholesterolemia, through the administration of specific antisense oligonucleotides. The core of the patent lies in its claims related to the chemical structure and therapeutic application of these molecules, targeting the messenger RNA (mRNA) of apolipoprotein B-100 (apoB-100).
What Is the Primary Therapeutic Target and Mechanism of Action?
The patent's primary therapeutic target is the production of apolipoprotein B-100 (apoB-100), a key protein component of low-density lipoprotein (LDL) cholesterol. The mechanism of action involves antisense oligonucleotides that bind to the messenger RNA (mRNA) encoding apoB-100. This binding event triggers the degradation of the apoB-100 mRNA, thereby reducing the synthesis of apoB-100 protein. Lower levels of apoB-100 lead to a decrease in circulating LDL cholesterol, a primary risk factor for cardiovascular disease.
What Are the Key Claims of Patent 8,293,756?
The patent's claims define the exclusive rights granted to Ionis Pharmaceuticals. These claims are segmented into independent and dependent claims, each specifying particular aspects of the invention.
Independent Claims
-
Claim 1: This is the foundational claim, defining a method for reducing plasma levels of apolipoprotein B-100 in a subject. The method comprises administering a therapeutically effective amount of an antisense oligonucleotide. The oligonucleotide is described by its chemical structure: an antisense oligonucleotide having at least one modified nucleotide. Specifically, the oligonucleotide comprises a sequence of 10-50 nucleotides that is complementary to a nucleotide sequence of human apoB-100 mRNA. A critical element of this claim is the inclusion of a modified nucleotide, specified as a 2'-O-methoxyethyl modified nucleotide, and at least one internucleoside linkage, specified as a phosphorothioate linkage.
-
Claim 14: This claim broadens the scope to a pharmaceutical composition for reducing plasma levels of apoB-100. The composition comprises a therapeutically effective amount of the antisense oligonucleotide defined in claim 1 and a pharmaceutically acceptable carrier.
Dependent Claims
Dependent claims further refine and narrow the scope of the independent claims, providing additional specificity and potentially broader coverage through variations.
-
Claims 2-13: These claims depend on Claim 1 and provide specific parameters and examples of the antisense oligonucleotide.
- Nucleotide Length: Claims specify ranges such as 10-30 nucleotides (Claim 2), 15-25 nucleotides (Claim 3), and 18-22 nucleotides (Claim 4).
- Complementarity Region: Claims define the specific region of the apoB-100 mRNA to which the oligonucleotide is complementary. This includes complementarity to the coding region (Claim 5), regions from nucleotide position 1 to 1000 of the apoB-100 mRNA (Claim 6), and specific ranges within the coding sequence (e.g., positions 200-1000, 500-1500) (Claims 7-9).
- Modified Nucleotides: Claims detail the incorporation of modified nucleotides. This includes oligonucleotides with 2'-O-methoxyethyl modified nucleotides in specific positions (Claims 10-12), such as every nucleotide or specific alternating patterns.
- Internucleoside Linkages: Claims specify the type of internucleoside linkages, with phosphorothioate linkages being a prominent feature (Claim 13).
-
Claims 15-21: These claims depend on Claim 14 and relate to the pharmaceutical composition. They specify the oligonucleotide as defined in any of the preceding claims (Claims 15-21), essentially linking the composition back to the specific oligonucleotide structures defined earlier.
What Is the Patent Landscape for ApoB-100 Targeting Oligonucleotides?
The patent landscape for apoB-100 targeting antisense oligonucleotides is dynamic, characterized by extensive patent filings from Ionis Pharmaceuticals and other entities. This landscape is shaped by scientific advancements in oligonucleotide synthesis, delivery mechanisms, and an increasing understanding of genetic regulation of lipid metabolism.
Key Players and Their Patents
-
Ionis Pharmaceuticals: As the assignee of Patent 8,293,756, Ionis holds a foundational position. Their portfolio includes numerous patents covering various antisense oligonucleotide designs, chemical modifications, and therapeutic applications targeting apoB-100 and other lipid-related genes. For example, patents related to their commercial drug mipomersen (Kynamro) and other pipeline candidates would overlap or relate to this patent's domain.
-
Other Pharmaceutical Companies: Several other major pharmaceutical companies have invested in oligonucleotide therapeutics. While specific patent numbers would require a detailed search, companies like Arrowhead Pharmaceuticals, Alnylam Pharmaceuticals, and Roche have active patent portfolios in RNA interference (RNAi) and antisense technology, which can overlap with targets like apoB-100. These companies often focus on different chemical modifications, delivery systems, or target genes within the lipid metabolism pathway.
Patent Trends and Strategies
-
Chemical Modifications: Early patents focused on basic antisense mechanisms. More recent filings emphasize novel chemical modifications to improve stability, reduce off-target effects, enhance cellular uptake, and prolong half-life. This includes modifications beyond 2'-O-methoxyethyl and phosphorothioate linkages, such as locked nucleic acids (LNAs) and peptide nucleic acids (PNAs), though Patent 8,293,756 specifically claims 2'-O-methoxyethyl.
-
Delivery Systems: Efficient delivery of oligonucleotides to target tissues (e.g., liver) remains a critical area. Patents increasingly cover conjugate chemistries (e.g., N-acetylgalactosamine conjugates for liver targeting) and novel formulation technologies to enhance delivery and efficacy.
-
Therapeutic Indications: While Patent 8,293,756 focuses on dyslipidemias, the broader landscape includes patents for treating genetic disorders, viral infections, and cancer using similar oligonucleotide technologies.
-
Exclusivity Strategies: Companies employ patent thickets and a series of related patents to extend market exclusivity beyond the life of a single patent. This includes patents on specific manufacturing processes, salt forms, polymorphs, and combination therapies.
Potential for Infringement and Litigation
Given the defined chemical structures and therapeutic methods in Patent 8,293,756, any new antisense oligonucleotide drug designed to reduce apoB-100 levels by targeting its mRNA using similar chemical modifications (2'-O-methoxyethyl and phosphorothioate linkages) and nucleotide sequences within the claimed range could potentially infringe on this patent. The broad claims concerning complementarity to various regions of the apoB-100 mRNA also present a wide scope for potential infringement.
How Do the Claims Compare to Marketed Products?
Patent 8,293,756's claims are foundational to antisense oligonucleotide therapeutics targeting apoB-100. The claims' specificity regarding the 2'-O-methoxyethyl modified nucleotide and phosphorothioate linkage directly influences which marketed products might be relevant for comparison.
Mipomersen (Kynamro)
Ionis Pharmaceuticals' mipomersen, marketed as Kynamro, is a notable example of an apoB-100 targeting antisense oligonucleotide. Mipomersen is an 18-mer antisense oligonucleotide with a gapmer structure: the central 10 nucleotides are DNA, and the flanking 4 nucleotides on each end are 2'-O-methoxyethyl modified RNA. All internucleoside linkages are phosphorothioate ( [1], [2]).
-
Alignment with Patent Claims: Mipomersen aligns directly with several key aspects of Patent 8,293,756. Its 18-nucleotide length falls within the claimed ranges (e.g., Claims 3 and 4). The 2'-O-methoxyethyl modification on specific nucleotides and the phosphorothioate linkages are explicitly recited in the patent's independent and dependent claims. While the specific sequence of mipomersen is proprietary and not directly in the patent, its chemical structure and mechanism of action (targeting apoB-100 mRNA) are within the scope of the patent's method claims.
-
Difference in Specificity: Patent 8,293,756 claims a method of reducing apoB-100 and compositions. Mipomersen is a specific drug product developed under the umbrella of such patents. The patent claims are broader than a single drug substance; they define a technology platform.
Other Potential Comparators
While mipomersen is a direct comparison due to its targeting and chemical structure, other lipid-lowering agents, even those not based on antisense technology, serve as market comparators in terms of therapeutic goals and patient populations.
-
PCSK9 Inhibitors (e.g., Evolocumab, Alirocumab): These are monoclonal antibodies that target PCSK9, a protein that degrades LDL receptors. By inhibiting PCSK9, these drugs increase the number of LDL receptors on liver cells, leading to lower LDL cholesterol. While highly effective in reducing LDL, their mechanism of action and chemical nature (protein vs. oligonucleotide) are distinct. However, they compete in the same therapeutic space for patients with hypercholesterolemia. Patent 8,293,756 claims an oligonucleotide-based therapy, not antibody-based ones.
-
Statins: These are widely prescribed HMG-CoA reductase inhibitors. They reduce cholesterol synthesis in the liver. Statins are a different class of drugs with a different mechanism and chemical structure, representing the baseline standard of care for hypercholesterolemia.
The claims of Patent 8,293,756, particularly those detailing specific chemical modifications and complementarity to apoB-100 mRNA, are highly relevant to the development and commercialization of antisense oligonucleotide drugs targeting apoB-100, such as mipomersen.
What Are the Implications for R&D and Investment?
The analysis of Patent 8,293,756 has significant implications for research and development (R&D) and investment decisions within the pharmaceutical and biotechnology sectors.
R&D Implications
-
Freedom to Operate (FTO): Any entity developing antisense oligonucleotides targeting apoB-100, especially those employing 2'-O-methoxyethyl modifications and phosphorothioate linkages, must conduct thorough FTO analysis against this patent and its related divisional or continuation applications. The broad claims on complementarity regions also necessitate careful sequence design to avoid infringement.
-
Innovation Pathways: The patent highlights specific chemical modifications. Future R&D may focus on:
- Alternative Chemical Modifications: Developing oligonucleotides with different sugar modifications (e.g., 2'-fluorine, 2'-methoxy) or backbone linkages (e.g., phosphorodiamidate morpholino oligomers) to circumvent existing patents while achieving similar efficacy.
- Different Target Genes: Exploring other genes involved in lipid metabolism or cardiovascular disease that are not covered by this patent.
- Novel Delivery Systems: Innovating in delivery mechanisms to enhance targeting and reduce the need for specific chemical backbone modifications that are heavily patented.
- Combination Therapies: Investigating combinations of apoB-100 targeting oligonucleotides with other therapeutic modalities, though patent claims on combinations also need to be considered.
-
Patent Expiration: Understanding the patent's expiration date (October 23, 2029, for the patent term adjustment) is crucial for forecasting the timeline for generic or biosimilar oligonucleotide development.
Investment Implications
-
Portfolio Diversification: Investors should assess portfolios of companies involved in oligonucleotide therapeutics. Diversification across different chemical modalities (siRNA, ASO, etc.) and therapeutic targets can mitigate risks associated with patent challenges and market exclusivity.
-
Valuation of Early-Stage Assets: For companies developing early-stage apoB-100 targeting oligonucleotides, the valuation will be heavily influenced by the FTO landscape and the remaining patent life of key patents like 8,293,756. Agreements with patent holders, such as licensing deals, will be critical.
-
Competition Analysis: Investors need to monitor the patenting activities of Ionis Pharmaceuticals and its competitors to identify emerging threats or opportunities. A strong patent portfolio signals market advantage and potential for sustained revenue.
-
Risk Assessment: The potential for patent litigation is a significant risk. Investors must consider the likelihood and impact of infringement lawsuits. The strength of the patent's claims, prior art, and prosecution history are key factors in this assessment.
-
Market Entry Timing: The expiration of key patents on oligonucleotide therapeutics will open the door for generic competition. Investors looking at companies developing follow-on products must align their investment horizons with these expiration dates.
Patent 8,293,756 serves as a cornerstone patent for a specific class of lipid-lowering oligonucleotide therapies. Its scope and claims necessitate careful navigation by any organization operating in this space, influencing both the direction of scientific inquiry and the strategic allocation of capital.
Key Takeaways
- Patent 8,293,756, assigned to Ionis Pharmaceuticals, covers methods and compositions for treating dyslipidemias by reducing apoB-100 through specific antisense oligonucleotides.
- The core claims specify oligonucleotides with 2'-O-methoxyethyl modified nucleotides and phosphorothioate linkages, complementary to human apoB-100 mRNA.
- The patent landscape for apoB-100 targeting oligonucleotides is competitive, with numerous filings from Ionis and other major pharmaceutical entities.
- Marketed products like mipomersen (Kynamro) align with the chemical and mechanistic claims of this patent.
- R&D and investment decisions must account for freedom-to-operate, alternative innovation pathways, and the patent's expiration date.
FAQs
-
What specific diseases are covered by Patent 8,293,756?
The patent explicitly covers methods for treating dyslipidemias, specifically hypercholesterolemia, by reducing plasma levels of apolipoprotein B-100.
-
Can other companies develop apoB-100 targeting antisense oligonucleotides?
Other companies can develop such oligonucleotides, but they must ensure their products do not infringe on the claims of Patent 8,293,756. This typically involves conducting thorough freedom-to-operate analyses and potentially designing around the patent's claims through different chemical modifications, sequences, or delivery methods.
-
What is the expiration date of Patent 8,293,756?
The patent term for United States Patent 8,293,756 is October 23, 2029, prior to any potential patent term adjustments.
-
What are the key chemical features claimed in the patent that differentiate its oligonucleotides?
The patent claims emphasize oligonucleotides containing at least one modified nucleotide, specifically a 2'-O-methoxyethyl modified nucleotide, and at least one internucleoside linkage, specifically a phosphorothioate linkage.
-
Does this patent cover RNA interference (RNAi) therapies targeting apoB-100?
Patent 8,293,756 is specifically focused on antisense oligonucleotides. While both antisense and RNAi are nucleic acid-based therapeutic modalities, they operate through distinct mechanisms and are often covered by different patent families. This patent's claims are tailored to the antisense mechanism.
Citations
[1] Kynamro (mipomersen sodium) Prescribing Information. (n.d.). Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203022s000lbl.pdf
[2] Investing.com. (n.d.). Ionis Pharmaceuticals, Inc. (IONS) Investor Relations. Retrieved from https://www.investing.com/equities/ionais-pharmaceuticals-inc-financial-data
More… ↓
⤷ Start Trial
|
